Focal therapy for prostate cancer: A potential strategy to address the problem of overtreatment;Terapia focal en cáncer de próstata: Una potencial estrategia para solucionar el problema del sobretratamiento

Archivos Espanoles de Urologia

Volumn 63, Issue 10, 2010, Pages 845-852

  Lecornet, Emilie ^a,b   Ahmed, Hashim Uddin ^a   Moore, Caroline ^a   Emberton, Mark ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Cryotherapy; Focal therapy; HIFU; Photodynamic therapy; Prostate cancer

Indexed keywords

ARTICLE; HUMAN; MALE; PROSTATE TUMOR;

HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 78651306984     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Marberger M, et al. New treatments for localized prostate cancer. Urol, 2008;72(6 Suppl): S36-43.
2. Ahmed HU, et al. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol, 2007;4(11):632-42.
3. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol, 2005;23(32):8165-9.
4. Zhou P, et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol, 2005;23(28):6992-8.
5. Ahmed HU and Emberton M. Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way? World J Urol, 2008;26(5):457-67.
6. Amin M, et al. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl, 2005; (216):20-33.
7. Antunes AA, et al. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy. BJU Int, 2005;96(9):1258-63.
8. Freedland SJ, et al. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol, 2003;169(6):2136-41.
9. Polascik TJ and Mouraviev V. Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients. Urol, 2009;74(4):726-30.
10. Bacon CG, et al. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol, 2001;166(5):1804-10.
11. Galbraith ME, Ramirez JM, and Pedro LW. Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups. Oncol Nurs Forum, 2001;28(3):551-60.
12. Litwin MS, et al. Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer, 2002;95(1):54-60.
13. Lindner U and Trachtenberg J. Focal therapy for localized prostate cancer-choosing the middle ground. Can Urol Assoc J, 2009;3(4):333-335.
14. Latini DM, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol, 2007;178(3 Pt 1): p. 826-31; discussion 831-2.
15. Dale W, et al. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer, 2005;104(3):467-78.
16. Pickles T, et al. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int, 2007;100(3):544-51.
17. Burnet KL, et al. Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int, 2007;100(3):540-3.
18. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol, 2006;24(1):46-50. (Pubitemid 43097357)
19. Black P. There is no role for focal therapy in prostate cancer. Can Urol Assoc J, 2009;3(4):331-332.
20. Johansson JE, et al. Natural history of early, localized prostate cancer. JAMA, 2004;291(22):2713-9.
21. Jayram G and Eggener SE. Patient selection for focal therapy of localized prostate cancer. Curr Opin Urol, 2009;19(3):268-73.
22. Hu JC, et al. Patterns of care for radical prostatectomy in the United States from 2003 to 2005. J Urol, 2008;180(5):1969-74.
23. Thuroff S, et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol, 2003;17(8):673-7.
24. Blana A, et al. Eight years' experience with highintensity focused ultrasonography for treatment of localized prostate cancer. Urol, 2008;72(6):1329-33; discussion 1333-4.
25. Ahmed HU, Moore C, and Emberton M. Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. Surg Oncol, 2009;18(3):219-32.
26. Ritch CR and Katz AE. Prostate cryotherapy: current status. Curr Opin Urol, 2009;19(2):177-81.
27. Onik G. Rationale for a "male lumpectomy", a prostate cancer targeted approach using cryoablation: results in 21 patients with at least 2 years of follow-up. Cardiovasc Intervent Radiol, 2008;31(1):98-106.
28. Onik G, et al. The "male lumpectomy": focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol, 2008;26(5):500-5.
29. Bahn DK, et al. Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol, 2006;20(9):688-92.
30. Ellis DS, Manny TB, and Rewcastle JC. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urol, 2007;70(6 Suppl): 9-15.
31. Lambert EH, et al. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology, 2007;69(6):1117-20.
32. Ritch CR and Katz AE. Update on cryotherapy for localized prostate cancer. Curr Urol Rep, 2009;10(3):206-11.
33. Emberton M. VTP for men with prostate cancer - Early Results. J Endourol, 2008;22:3.
34. Tareen B, et al. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer? BJU Int, 2009;104(2):195-9.
35. Sartor AO, et al. Evaluating localized prostate cancer and identifying candidates for focal therapy. Urol, 2008:72 (6 Suppl): S12-24.
36. Bostwick DG, et al. Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006. Urol, 2007;70(6 Suppl): 42-4.
37. Onik G and Barzell W. Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol, 2008;26(5):506-10.
38. Tsivian M, et al. Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. BJU Int, 2009.
39. Crawford ED, et al. Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. BJU Int, 2005;96(7):999-1004.
40. Turpen R and Rosser CJ. Focal therapy for prostate cancer: revolution or evolution? BMC Urol, 2009;9:2.
41. Barzell WE and Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate-a 4-year experience. Urol, 2007;70(6 Suppl): 27-35.
42. Turkbey B, et al. Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol, 2009;192(6):1471-80.
43. Turkbey B, Pinto PA, and Choyke PL. Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol, 2009;6(4):191-203.
44. Yang JC, et al. Contrast-enhanced gray-scale transrectal ultrasound-guided prostate biopsy in men with elevated serum prostate-specific antigen levels. Acad Radiol, 2008;15(10):1291-7.
45. Tang J, et al. Peripheral zone hypoechoic lesions of the prostate: evaluation with contrast-enhanced gray scale transrectal ultrasonography. J Ultrasound Med, 2007;26(12):1671-9.
46. Halpern EJ, et al. Detection of prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging. Cancer, 2005;104(11):2373-83.
47. Braeckman J, et al. Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int, 2008;101(3):293-8.
48. Braeckman J, et al. The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int, 2008;102(11):1560-5.
49. Ahmed HU, et al. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol, 2009;6(4):197-206.
50. Krieger A, et al. Design of a novel MRI compatible manipulator for image guided prostate interventions. IEEE Trans Biomed Eng, 2005;52(2):306-13.
51. Atri M, et al, Contrast-enhanced ultrasonography for real-time monitoring of interstitial laser thermal therapy in the focal treatment of prostate cancer. Can Urol Assoc J, 2009;3(2):125-30.
52. Lindner U, et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol, 2009;182(4):1371-7.
53. McNichols RJ, et al. MR thermometry-based feedback control of laser interstitial thermal therapy at 980 nm. Lasers Surg Med, 2004;34(1):48-55.
54. de Senneville BD, Mougenot C, and Moonen CT. Real-time adaptive methods for treatment of mobile organs by MRI-controlled high-intensity focused ultrasound. Magn Reson Med, 2007;57(2):319-30.
55. de Senneville BD, et al. MR thermometry for monitoring tumor ablation. Eur Radiol, 2007;17(9):2401-10.
56. Mougenot C, et al. Three-dimensional spatial and temporal temperature control with MR thermometry-guided focused ultrasound (MRgHIFU). Magn Reson Med, 2009;61(3):603-14.
57. Mouraviev V, et al. Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. Technol Cancer Res Treat, 2007;6(2):91-5.
58. Mouraviev V, Polascik TJ, Pathological background and its clinical implications for focal therapy of early detected prostate cancer. Nat Clin Pract Urol., in press.
59. Mouraviev V, et al. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer, 2007;110(4):906-10.
60. Tareen B, et al. Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort. Urol, 2009;73(2):351-4; discussion 354-5.
61. De Laet K, et al. Predicting tumour location in radical prostatectomy specimens: same-patient comparisons of 21-sample versus sextant biopsy. BJU Int, 2009;104(5):616-20.
62. Villers A, et al. Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance. Curr Opin Urol, 2009;19(3):274-82.
63. Nelson BA, et al. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int, 2006;97(6):1169-72.
64. Villers A, et al. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer, 1992;70(9):2313-8.
65. Iczkowski KA, et al. Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. Urol, 2008;71(6):1166-71.
66. Noguchi M, et al. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol, 2003;170(2 Pt 1):459-63.
67. Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med, 2009;361(17):1704-6.
68. Eggener SE, et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol, 2007;178(6):2260-7.